IPHYF: AI 评分 44/100 — AI 分析 (4月 2026)

Innate Pharma S.A. is a French biotechnology company focused on developing immunotherapies for cancer. Their pipeline includes multiple clinical-stage assets targeting various cancers, with strategic collaborations to bolster research and development.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Innate Pharma S.A., a French biotechnology firm, specializes in developing innovative immunotherapies for cancer, focusing on NK cell biology and antibody engineering. With a diverse pipeline of clinical-stage assets and strategic partnerships, the company aims to address unmet needs in cancer treatment on a global scale.

IPHYF是做什么的？

Innate Pharma S.A., founded in 1999 and based in Marseille, France, is a biotechnology company dedicated to discovering, developing, and commercializing innovative immunotherapies for cancer. The company's focus is on harnessing the innate immune system to fight cancer, particularly through Natural Killer (NK) cell biology and antibody engineering. Innate Pharma's pipeline includes several clinical-stage assets, such as Lacutamab (IPH4102), an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is in Phase III trials for advanced solid tumors including colorectal, lung, and head and neck cancers. Other assets include IPH5201, IPH5301, IPH6401, IPH6101, and IPH62, targeting various immunosuppressive pathways and tumor antigens. The company also has preclinical programs like IPH43, IPH45, and IPH67. Innate Pharma collaborates with pharmaceutical companies like AstraZeneca, Novo Nordisk A/S, Sanofi, and MedImmune Limited to advance its research and development efforts. The company operates internationally, seeking to address unmet medical needs in cancer treatment worldwide.

IPHYF的投资论点是什么？

Innate Pharma presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's focus on innovative immunotherapies, particularly those targeting NK cells, positions it at the forefront of cancer treatment advancements. Key value drivers include the successful progression of Lacutamab and Monalizumab through clinical trials, with potential FDA approval representing significant upside. Strategic collaborations with major pharmaceutical companies like AstraZeneca and Sanofi provide financial support and validation of Innate Pharma's technology. However, the company's negative gross margin of -243.7% and high debt-to-equity ratio of 525.45 indicate financial challenges. Successful clinical trial outcomes and partnership expansions are crucial for long-term value creation.

IPHYF在哪个行业运营？

Innate Pharma operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The immunotherapy market, in which Innate Pharma specializes, is experiencing substantial growth, driven by the increasing prevalence of cancer and advancements in immune-based therapies. Key trends include the development of novel checkpoint inhibitors, cell therapies, and antibody-drug conjugates. Innate Pharma competes with established pharmaceutical companies and other biotechnology firms, striving to differentiate itself through its focus on NK cell biology and strategic collaborations.

Biotechnology

Healthcare

IPHYF有哪些增长机遇？

Growth opportunity 1: Successful clinical trials and regulatory approvals for Lacutamab (IPH4102) represent a significant growth opportunity. The drug is currently in Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory sézary syndrome. Positive trial results and subsequent FDA approval could lead to substantial revenue generation, addressing a market with unmet medical needs. The timeline for potential approval is dependent on trial outcomes, but could be within the next 2-3 years.
Growth opportunity 2: Advancing Monalizumab through Phase III clinical trials for advanced solid tumors, including colorectal, lung, and head and neck cancers, offers another key growth avenue. Positive results and subsequent commercialization could significantly expand Innate Pharma's market reach and revenue streams. The potential market for these indications is substantial, with a timeline for potential approval within the next 2-4 years.
Growth opportunity 3: Expanding strategic collaborations with pharmaceutical companies like AstraZeneca, Novo Nordisk A/S, and Sanofi provides financial resources and expertise to accelerate drug development. These partnerships can lead to milestone payments, royalties, and co-development opportunities, enhancing Innate Pharma's long-term growth prospects. The ongoing collaborations are expected to continue driving innovation and value creation.
Growth opportunity 4: Developing and commercializing new NK cell engagers, such as IPH6401 and IPH6101, targeting BCMA and CD123, respectively, represents a promising growth area. These innovative therapies have the potential to address unmet needs in hematological malignancies and other cancers. The timeline for potential commercialization is dependent on preclinical and clinical trial progress, but could be within the next 3-5 years.
Growth opportunity 5: Progressing preclinical programs like IPH43, IPH45, and IPH67 into clinical development offers long-term growth potential. These early-stage assets target various tumor antigens and immunosuppressive pathways, providing opportunities to expand Innate Pharma's pipeline and address a broader range of cancers. The timeline for potential clinical trials is dependent on preclinical data, but could be within the next 1-2 years.

Market capitalization of $0.19 billion reflects the company's current valuation in the biotechnology market.
Gross margin of -243.7% indicates significant costs associated with research and development activities.
Return on Equity (ROE) of -271.4% suggests challenges in generating profits from shareholders' equity.
Debt-to-Equity ratio of 525.45 indicates a high level of financial leverage.
Free Cash Flow (FCF) of $-0.00B reflects ongoing investment in research and development.

IPHYF提供哪些产品和服务？

Develop immunotherapies for cancer patients.
Focus on harnessing the innate immune system to fight cancer.
Develop Natural Killer (NK) cell-based therapies.
Engineer antibodies to target specific cancer cells.
Conduct clinical trials to evaluate the safety and efficacy of their therapies.
Collaborate with pharmaceutical companies to advance research and development.
Target immunosuppressive pathways to promote antitumor immunity.

IPHYF如何赚钱？

Develop and out-license novel immunotherapies to larger pharmaceutical companies.
Generate revenue through milestone payments and royalties from partnered programs.
Retain rights to certain programs for independent development and commercialization.
Collaborate with research institutions to identify and validate new drug targets.

Cancer patients in need of innovative treatment options.
Pharmaceutical companies seeking to expand their oncology portfolios.
Research institutions and academic centers involved in cancer research.
Healthcare providers who prescribe and administer cancer therapies.

Proprietary NK cell biology expertise.
Strong intellectual property portfolio covering key drug candidates.
Strategic collaborations with leading pharmaceutical companies.
Advanced antibody engineering capabilities.

什么因素可能推动IPHYF股价上涨？

Upcoming: Phase II clinical trial results for Lacutamab (IPH4102) in cutaneous T-cell and peripheral T-cell lymphoma.
Upcoming: Phase III clinical trial results for Monalizumab in advanced solid tumors.
Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
Ongoing: Progress in preclinical development of new NK cell engagers.
Ongoing: Potential for FDA approval of key drug candidates.

IPHYF的主要风险是什么？

Potential: Clinical trial failures for key drug candidates.
Potential: Regulatory setbacks or delays.
Ongoing: Competition from other immunotherapy companies.
Ongoing: High research and development costs.
Ongoing: Financial challenges due to negative gross margin and high debt.

IPHYF的核心优势是什么？

Innovative immunotherapy pipeline.
Focus on NK cell biology.
Strategic collaborations with major pharmaceutical companies.
Experienced management team.

IPHYF的劣势是什么？

Negative gross margin.
High debt-to-equity ratio.
Reliance on clinical trial success.
Limited commercialization experience.

IPHYF有哪些机遇？

Successful clinical trial outcomes.
Regulatory approvals for key drug candidates.
Expansion of strategic collaborations.
Development of new NK cell-based therapies.

IPHYF面临哪些威胁？

Clinical trial failures.
Regulatory setbacks.
Competition from other immunotherapy companies.
Patent expirations.

IPHYF的竞争对手是谁？

AstraZeneca — Major pharmaceutical company with a broad oncology portfolio. — (AZN)
Sanofi — Global healthcare company with a focus on oncology and immunology. — (SNY)

Key Metrics

MoonshotScore: 44/100

Company Profile

Headquarters: Marseille, France
Employees: 174

AI Insight

AI analysis pending for IPHYF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Innate Pharma S.A. do?

Innate Pharma S.A. is a biotechnology company focused on developing innovative immunotherapies for cancer. The company's research is centered around harnessing the power of the innate immune system, particularly Natural Killer (NK) cells, to fight cancer. Their pipeline includes clinical-stage assets like Lacutamab and Monalizumab, which target specific cancers and immunosuppressive pathways. Innate Pharma collaborates with major pharmaceutical companies to advance its research and development efforts, aiming to address unmet medical needs in cancer treatment globally.

What do analysts say about IPHYF stock?

AI analysis is currently pending for IPHYF stock. Generally, biotechnology stocks are evaluated based on the potential of their drug pipeline, clinical trial results, and partnerships. Key valuation metrics include market capitalization, cash burn rate, and potential revenue from future drug sales. Growth considerations involve the successful progression of clinical trials, regulatory approvals, and market adoption of their therapies. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for IPHYF?

Innate Pharma faces several risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results can halt drug development and impact the company's valuation. Regulatory setbacks, such as delays or rejections of drug approvals, can also negatively affect the company. Competition from other immunotherapy companies and the high costs associated with research and development are ongoing challenges. Additionally, Innate Pharma's negative gross margin and high debt-to-equity ratio indicate financial vulnerabilities that could impact its ability to fund future growth.